# EDGAR Filing Document

**Accession Number:** 0001371285
**File Stem:** 0001371285-23-000040
**Filing Date:** 2023-2
**Character Count:** 43413
**Document Hash:** 5fe1c0254c56e9e8f15d06086fe972bf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001371285-23-000040.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001371285-23-000040

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230215

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TRUPANION, INC.
- **CENTRAL INDEX KEY:** 0001371285
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36537
- **FILM NUMBER:** 23635342

**BUSINESS ADDRESS:**
- **STREET 1:** 6100 4TH AVENUE SOUTH
- **STREET 2:** SUITE 400
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98108
- **BUSINESS PHONE:** 888-733-2685

**MAIL ADDRESS:**
- **STREET 1:** 6100 4TH AVENUE SOUTH
- **STREET 2:** SUITE 400
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRUPANION INC.
- **DATE OF NAME CHANGE:** 20131114

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VETINSURANCE INTERNATIONAL INC
- **DATE OF NAME CHANGE:** 20060802

?xml version="1.0" ? trup-20230215

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 15, 2023** 

**TRUPANION, INC.** 

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36537** | **83-0480694** |
| **(State or other jurisdiction of**<br>**incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**6100 4th Avenue S, Suite 400** 

**Seattle, Washington 98108** 

**(Address of principal executive offices, including zip code)**

**(855) 727 - 9079** 

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| <u>Title of each class</u> | <u>Trading Symbol</u> | <u>Name of each exchange on which registered</u> |
| Common stock, $0.00001 par value per share | TRUP | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 &nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On February 15, 2023, Trupanion, Inc. (the "Company") issued a press release regarding the Company's financial results for the quarter ended December 31, 2022. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

---

| | | |
|:---|:---|:---|
| **(d)** | **Exhibits** | |
| | <u>Exhibit No.</u> | <u>Description</u> |
| | <u>[99.1](ex991q42022.htm)</u> | Press release regarding financial results issued by Trupanion, Inc. dated February 15, 2023 |
| | 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **TRUPANION, INC.** | **TRUPANION, INC.** |
| By: | /s/ Drew Wolff |
|  | Name: Drew Wolff |
|  | Title: Chief Financial Officer |

---

Date: February 15, 2023

## Exhibit 99.1

**<u>Exhibit 99.1</u>**

![trulogoenrgb2018a02.jpg](trulogoenrgb2018a02.jpg)

**Trupanion Reports Fourth Quarter and Full Year 2022 Results**

SEATTLE, WA. February 15, 2023 -- <u>Trupanion</u>, Inc. (Nasdaq: TRUP), the leading provider of medical insurance for cats and dogs, today announced financial results for the fourth quarter and full year ended December 31, 2022.

"2022 was another year of consistent revenue growth and we set solid foundations for our long-term growth initiatives, leading to the doubling of our addressable market," said Darryl Rawlings, founder and chief executive officer of Trupanion. "With our work over the last 24 months and the opportunities ahead of us, 2023 will be an exciting year. We will remain disciplined in our cash deployment and focused on earning strong internal rates of return."

**Full Year 2022 Financial and Business Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total revenue was $905.2 million, an increase of 29% compared to 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total enrolled pets (including pets from our other business segment) was 1,537,573 at December 31, 2022, an increase of 31% over 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Subscription business revenue was $596.6 million, an increase of 21% compared to 2021 (22% on a constant currency basis).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Subscription enrolled pets was 869,862 at December 31, 2022, an increase of 24% over 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss was $(44.7) million, or $(1.10) per basic and diluted share, compared to net loss of $(35.5) million, or $(0.89) per basic and diluted share, in 2021. Net loss per share is inclusive of stock-based compensation expense of $0.80 and $0.70 for the year ended December 31, 2022 and December 31, 2021, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA was $0.7 million, compared to adjusted EBITDA of $4.7 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating cash flow was $(8.0) million and free cash flow was $(25.1) million in 2022. This compared to operating cash flow of $7.5 million and free cash flow of $(4.9) million in 2021.

**Fourth Quarter 2022 Financial and Business Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total revenue was $246.0 million, an increase of 27% compared to the fourth quarter of 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Subscription business revenue was $158.6 million, an increase of 18% compared to the fourth quarter of 2021 (20% on a constant currency basis).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss was $(9.3) million, or $(0.23) per basic and diluted share, compared to net loss of $(7.0) million, or $(0.17) per basic and diluted share, in the fourth quarter of 2021. Net loss per share is inclusive of stock-based compensation expense of $0.21 and $0.17 for the three months ended December 31, 2022 and December 31, 2021, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA was $2.2 million, compared to adjusted EBITDA of $3.5 million in the fourth quarter of 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating cash flow was $1.0 million and free cash flow was $(4.5) million in the fourth quarter of 2022. This compared to operating cash flow of $5.2 million and free cash flow of $1.3 million in the fourth quarter of 2021.

------

![totalrevbyquarter12-31x22.jpg](totalrevbyquarter12-31x22.jpg)

**Conference Call**

Trupanion's management will host a conference call today to review its fourth quarter and full year 2022 results. The call is scheduled to begin shortly after 1:30 p.m. PT/ 4:30 p.m. ET. A live webcast will be accessible through the Investor Relations section of Trupanion's website at <u>https://investors.trupanion.com/</u> and will be archived online for 3 months upon completion of the conference call. Participants can access the conference call by dialing 1-877-407-0784 (United States) or 1-201-689-8560 (International). A telephonic replay of the call will also be available after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 13735524.

**About Trupanion**

Trupanion is a leader in medical insurance for cats and dogs throughout the United States, Canada, Europe, Puerto Rico and Australia with over 800,000 pets enrolled. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. Trupanion is committed to providing pet owners with the highest value in pet medical insurance with unlimited payouts for the life of their pets. With its patented process, Trupanion is the only North American provider with the technology to pay veterinarians directly in seconds at the time of checkout. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by Omega General Insurance Company. Trupanion Australia is a partnership between Trupanion and Hollard Insurance Company. For more information, please visit <u>trupanion.com</u>.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to, among other things, expectations, plans, prospects and financial results for Trupanion, including, but not limited to, its expectations regarding its ability to continue to grow its enrollments and revenue, and otherwise execute its business plan. These forward-looking statements are based upon the current expectations and beliefs of Trupanion's management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements made in this press release are based on information available to Trupanion as of the date hereof, and Trupanion has no obligation to update these forward-looking statements.

------

In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the ability to achieve or maintain profitability and/or appropriate levels of cash flow in future periods; the ability to keep growing our membership base and revenue; the accuracy of assumptions used in determining appropriate member acquisition expenditures; the severity and frequency of claims; the ability to maintain high retention rates; the accuracy of assumptions used in pricing medical plan subscriptions and the ability to accurately estimate the impact of new products or offerings on claims frequency; actual claims expense exceeding estimates; regulatory and other constraints on the ability to institute, or the decision to otherwise delay, pricing modifications in response to changes in actual or estimated claims expense; the effectiveness and statutory or regulatory compliance of our Territory Partner model and of our Territory Partners, veterinarians and other third parties in recommending medical plan subscriptions to potential members; the ability to retain existing Territory Partners and increase the number of Territory Partners and active hospitals; compliance by us and those referring us members with laws and regulations that apply to our business, including the sale of a pet medical plan; the ability to maintain the security of our data; fluctuations in the Canadian currency exchange rate; the ability to protect our proprietary and member information; the ability to maintain our culture and team; the ability to maintain the requisite amount of risk-based capital; our ability to implement and maintain effective controls, including over financial reporting; the ability to protect and enforce Trupanion's intellectual property rights; the ability to successfully implement our alliance with Aflac; the ability to continue key contractual relationships with third parties; third-party claims including litigation and regulatory actions; the ability to recognize benefits from investments in new solutions and enhancements to Trupanion's technology platform and website; and our ability to retain key personnel.

For a detailed discussion of these and other cautionary statements, please refer to the risk factors discussed in filings with the Securities and Exchange Commission (SEC), including but not limited to, Trupanion's Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequently filed reports on Forms 10-Q, 10-K and 8-K. All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval system at <u>https://www.sec.gov/</u> or the Investor Relations section of Trupanion's website at <u>https://investors.trupanion.com/.</u>

**Non-GAAP Financial Measures**

Trupanion's stated results may include certain non-GAAP financial measures. These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in its industry as other companies in its industry may calculate or use non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on Trupanion's reported financial results. The presentation and utilization of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Trupanion urges its investors to review the reconciliation of its non-GAAP financial measures to the most directly comparable GAAP financial measures in its consolidated financial statements, and not to rely on any single financial or operating measure to evaluate its business. These reconciliations are included below and on <u>Trupanion's Investor Relations website</u>.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company's non-cash expenses, Trupanion believes that providing various non-GAAP financial measures that exclude stock-based compensation expense and depreciation and amortization expense allows for more meaningful comparisons between its operating results from period to period. Trupanion offsets new pet acquisition expense with sign-up fee revenue in the calculation of net acquisition cost because it collects sign-up fee revenue from new members at the time of enrollment and considers it to be an offset to a portion of Trupanion's new pet acquisition expense. Trupanion believes this allows it to calculate and present financial measures in a consistent manner across periods. Trupanion's management believes that the non-GAAP financial measures and the related financial measures derived from them are important tools for financial and operational decision-making and for evaluating operating results over different periods of time.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Trupanion, Inc.<br>Consolidated Statements of Operations<br>(in thousands, except share data)** | **Trupanion, Inc.<br>Consolidated Statements of Operations<br>(in thousands, except share data)** | **Trupanion, Inc.<br>Consolidated Statements of Operations<br>(in thousands, except share data)** | **Trupanion, Inc.<br>Consolidated Statements of Operations<br>(in thousands, except share data)** | **Trupanion, Inc.<br>Consolidated Statements of Operations<br>(in thousands, except share data)** |
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
|  | *(unaudited)* | *(unaudited)* |  |  |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Subscription business | $158562 | $134120 | $596610 | $494862 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other business | 87447 | 60259 | 308569 | 204129 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 246009 | 194379 | 905179 | 698991 |
| Cost of revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Subscription business<sup>(1)</sup> | 131823 | 108627 | 497684 | 407664 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other business | 80537 | 55217 | 285310 | 186981 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost of revenue<sup>(2)</sup> | 212360 | 163844 | 782994 | 594645 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology and development<sup>(1)</sup> | 6955 | 4665 | 25133 | 16866 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative<sup>(1)</sup> | 10472 | 8996 | 39379 | 31893 |
| &nbsp;&nbsp;&nbsp;&nbsp;New pet acquisition expense<sup>(1)</sup> | 22457 | 19845 | 89500 | 78647 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 2897 | 2770 | 10921 | 11965 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 42781 | 36276 | 164933 | 139371 |
| Loss from investment in joint venture | (85) | (22) | (253) | (171) |
| Operating loss | (9217) | (5763) | (43001) | (35196) |
| Interest expense | 1587 | 9 | 4267 | 10 |
| Other expense (income), net | (1504) | 236 | (3072) | 14 |
| Loss before income taxes | (9300) | (6008) | (44196) | (35220) |
| Income tax expense | (15) | 1034 | 476 | 310 |
| Net loss | $(9285) | $(7042) | $(44672) | $(35530) |
| Net loss per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | $(0.23) | $(0.17) | $(1.10) | $(0.89) |
| Weighted average shares of common stock outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | 40936507 | 40413434 | 40765355 | 40137505 |
| <sup>(1)</sup>Includes stock-based compensation expense as follows: | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| <sup>(1)</sup>Includes stock-based compensation expense as follows: | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Cost of revenue | $1346 | $1379 | $6484 | $7148 |
| Technology and development | 1549 | 843 | 4742 | 3056 |
| General and administrative | 3550 | 2450 | 12831 | 8862 |
| New pet acquisition expense | 2122 | 2136 | 9336 | 9160 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation expense | $8567 | $6808 | $33393 | $28226 |
| <sup>(2)</sup>The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows: | <sup>(2)</sup>The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows: | <sup>(2)</sup>The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows: | <sup>(2)</sup>The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows: | <sup>(2)</sup>The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows: |
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| &nbsp;&nbsp;&nbsp;&nbsp;Veterinary invoice expense | $176083 | $132852 | $649737 | $486062 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other cost of revenue | 36277 | 30992 | 133257 | 108583 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total cost of revenue | $212360 | $163844 | $782994 | $594645 |

---

------

---

| | | |
|:---|:---|:---|
| **Trupanion, Inc.<br>Consolidated Balance Sheets<br>(in thousands, except share data)** | **Trupanion, Inc.<br>Consolidated Balance Sheets<br>(in thousands, except share data)** | **Trupanion, Inc.<br>Consolidated Balance Sheets<br>(in thousands, except share data)** |
| | **December 31, 2022** | **December 31, 2021** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $65605 | $87400 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 156804 | 126012 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and other receivables, net of allowance for doubtful accounts of $540 at December 31, 2022 and $342 at December 31, 2021 | 232439 | 165217 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 14248 | 12325 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 469096 | 390954 |
| Restricted cash | 19032 | 13469 |
| Long-term investments | 7841 | 7061 |
| Property and equipment, net | 90701 | 77950 |
| Intangible assets, net | 24031 | 22663 |
| Other long-term assets | 18943 | 17776 |
| Goodwill | 41983 | 32709 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $671627 | $562582 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $9471 | $8952 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities and other current liabilities | 32616 | 28162 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reserve for veterinary invoices | 43734 | 39671 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 202692 | 146911 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt - current portion | 1103 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 289616 | 223696 |
| Long-term debt | 68354 |  |
| Deferred tax liabilities | 3392 | 2827 |
| Other liabilities | 4968 | 3859 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 366330 | 230382 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 42,041,344 and 41,013,158 shares issued and outstanding at December 31, 2022; 41,408,350 and 40,475,185 shares issued and outstanding at December 31, 2021 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 499694 | 466792 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (6301) | 3077 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (171562) | (126890) |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost: 1,028,186 and 933,165 shares at December 31, 2022 and 2021 | (16534) | (10779) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 305297 | 332200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $671627 | $562582 |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Trupanion, Inc.<br>Consolidated Statements of Cash Flows<br>(in thousands)** | **Trupanion, Inc.<br>Consolidated Statements of Cash Flows<br>(in thousands)** | **Trupanion, Inc.<br>Consolidated Statements of Cash Flows<br>(in thousands)** | **Trupanion, Inc.<br>Consolidated Statements of Cash Flows<br>(in thousands)** | **Trupanion, Inc.<br>Consolidated Statements of Cash Flows<br>(in thousands)** |
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
|  | *(unaudited)* | *(unaudited)* |  |  |
| **Operating activities** |  |  |  |  |
| Net loss | $(9285) | $(7042) | $(44672) | $(35530) |
| Adjustments to reconcile net loss to cash provided by (used in) operating activities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 2897 | 2770 | 10921 | 11965 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 8567 | 6808 | 33393 | 28226 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 1023 | (996) | 1051 | (1927) |
| Changes in operating assets and liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and other receivables | (8034) | (7397) | (66982) | (66170) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (807) | (1133) | (5227) | (3055) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable, accrued liabilities, and other liabilities | 2388 | 4443 | 3136 | 8796 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reserve for veterinary invoices | 4164 | 914 | 4227 | 10768 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 106 | 6789 | 56153 | 54385 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities | 1019 | 5156 | (8000) | 7458 |
| **Investing activities** |  |  |  |  |
| Purchases of investment securities | (147346) | (33384) | (273006) | (95672) |
| Maturities and sales of investment securities | 134718 | 18803 | 239210 | 57869 |
| Cash paid in business acquisition, net of cash acquired | (12279) |  | (15034) |  |
| Purchases of property and equipment | (5478) | (3818) | (17088) | (12355) |
| Other | (167) | (1707) | (1598) | (1755) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | (30552) | (20106) | (67516) | (51913) |
| **Financing activities** |  |  |  |  |
| Repurchase of common stock |  |  | (5755) |  |
| Proceeds from exercise of stock options | 706 | 551 | 2290 | 3607 |
| Shares withheld to satisfy tax withholding | (579) | (1002) | (4359) | (4732) |
| Proceeds from debt financing, net of financing fees | 14826 |  | 69138 |  |
| Repayment of debt financing | (271) |  | (571) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities | 14682 | (451) | 60743 | (1125) |
| Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net | 505 | 305 | (1459) | 252 |
| Net change in cash, cash equivalents, and restricted cash | (14346) | (15096) | (16232) | (45328) |
| Cash, cash equivalents, and restricted cash at beginning of period | 98983 | 115965 | 100869 | 146197 |
| Cash, cash equivalents, and restricted cash at end of period | $84637 | $100869 | $84637 | $100869 |

---

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| The following tables set forth our key operating metrics: | The following tables set forth our key operating metrics: | The following tables set forth our key operating metrics: | The following tables set forth our key operating metrics: | The following tables set forth our key operating metrics: | The following tables set forth our key operating metrics: | The following tables set forth our key operating metrics: | The following tables set forth our key operating metrics: | The following tables set forth our key operating metrics: |
|  | **Year Ended December 31,** | **Year Ended December 31,** |  |  |  |  |  |  |
|  | **Year Ended December 31,** | **Year Ended December 31,** |  |  |  |  |  |  |
|  | **2022** | **2021** |  |  |  |  |  |  |
| Total Business: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total pets enrolled (at period end) | 1537573 | 1176778 |  |  |  |  |  |  |
| Subscription Business: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total subscription pets enrolled (at period end) | 869862 | 704333 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Monthly average revenue per pet | $63.82 | $63.56 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Lifetime value of a pet, including fixed expenses | $641 | $717 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Average pet acquisition cost (PAC) | $289 | $287 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Average monthly retention | 98.69% | 98.74% |  |  |  |  |  |  |
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
|  | **Dec. 31, 2022** | **Sept. 30, 2022** | **Jun. 30, 2022** | **Mar. 31, 2022** | **Dec. 31, 2021** | **Sept. 30, 2021** | **Jun. 30, 2021** | **Mar. 31, 2021** |
| Total Business: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total pets enrolled (at period end) | 1537573 | 1439605 | 1348145 | 1267253 | 1176778 | 1104376 | 1024226 | 943854 |
| Subscription Business: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total subscription pets enrolled (at period end) | 869862 | 808077 | 770318 | 736691 | 704333 | 676463 | 643395 | 609835 |
| &nbsp;&nbsp;&nbsp;&nbsp;Monthly average revenue per pet | $63.11 | $63.80 | $64.26 | $64.21 | $63.89 | $63.60 | $63.69 | $62.97 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lifetime value of a pet, including fixed expenses | $641 | $673 | $713 | $730 | $717 | $697 | $681 | $684 |
| &nbsp;&nbsp;&nbsp;&nbsp;Average pet acquisition cost (PAC) | $283 | $268 | $309 | $301 | $306 | $280 | $284 | $279 |
| &nbsp;&nbsp;&nbsp;&nbsp;Average monthly retention | 98.69% | 98.71% | 98.74% | 98.75% | 98.74% | 98.72% | 98.72% | 98.73% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| The following table reflects the reconciliation of cash provided by (used in) operating activities to free cash flow (in thousands): | The following table reflects the reconciliation of cash provided by (used in) operating activities to free cash flow (in thousands): | The following table reflects the reconciliation of cash provided by (used in) operating activities to free cash flow (in thousands): | The following table reflects the reconciliation of cash provided by (used in) operating activities to free cash flow (in thousands): | The following table reflects the reconciliation of cash provided by (used in) operating activities to free cash flow (in thousands): |
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Net cash provided (used) by operating activities | $1019 | $5156 | $(8000) | $7458 |
| Purchases of property and equipment | (5478) | (3818) | (17088) | (12355) |
| Free cash flow | $(4459) | $1338 | $(25088) | $(4897) |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| The following table reflects the reconciliation between GAAP and non-GAAP measures (in thousands, except percentages): | The following table reflects the reconciliation between GAAP and non-GAAP measures (in thousands, except percentages): | The following table reflects the reconciliation between GAAP and non-GAAP measures (in thousands, except percentages): | The following table reflects the reconciliation between GAAP and non-GAAP measures (in thousands, except percentages): | The following table reflects the reconciliation between GAAP and non-GAAP measures (in thousands, except percentages): |
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Veterinary invoice expense | $176083 | $132852 | $649737 | $486062 |
| Excluding: |  |  |  |  |
| &nbsp;&nbsp;Stock-based compensation expense | (899) | (798) | (4054) | (4538) |
| &nbsp;&nbsp;Other business cost of paying veterinary invoices | (59946) | (38009) | (212857) | (129614) |
| **Subscription cost of paying veterinary invoices** | $115238 | $94045 | $432826 | $351910 |
| % of subscription revenue | 72.7% | 70.1% | 72.5% | 71.1% |
| Other cost of revenue | $36277 | $30992 | $133257 | $108583 |
| Excluding: |  |  |  |  |
| &nbsp;&nbsp;Stock-based compensation expense | (414) | (581) | (2232) | (2610) |
| &nbsp;&nbsp;Other business variable expenses | (20591) | (17208) | (72453) | (57367) |
| **Subscription variable expenses** | $15272 | $13203 | $58572 | $48606 |
| % of subscription revenue | 9.6% | 9.8% | 9.8% | 9.8% |
| Technology and development expense | $6955 | $4665 | $25133 | $16866 |
| General and administrative expense | 10472 | 8996 | 39379 | 31893 |
| Excluding: |  |  |  |  |
| &nbsp;&nbsp;Stock-based compensation expense | (5019) | (3293) | (17135) | (11918) |
| &nbsp;&nbsp;Development expenses<sup>1</sup> | (2084) | (858) | (7789) | (3719) |
| &nbsp;&nbsp;Business combination transaction costs | (193) |  | (372) | (82) |
| **Fixed expenses** | $10131 | $9510 | $39216 | $33040 |
| % of total revenue | 4.1% | 4.9% | 4.3% | 4.7% |
| New pet acquisition expense | $22457 | $19845 | $89500 | $78647 |
| Excluding: |  |  |  |  |
| &nbsp;&nbsp;Stock-based compensation expense | (2079) | (2136) | (9116) | (9160) |
| &nbsp;&nbsp;Other business pet acquisition expense | (65) | (76) | (541) | (499) |
| **Subscription acquisition cost** | $20313 | $17633 | $79843 | $68988 |
| % of subscription revenue | 12.8% | 13.1% | 13.4% | 13.9% |
| <sup>1</sup>As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend. | <sup>1</sup>As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend. | <sup>1</sup>As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend. | <sup>1</sup>As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend. | <sup>1</sup>As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend. |

---

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands): | The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands): | The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands): | The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands): | The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands): | The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands): | The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands): | The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands): | The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands): |
|  | **Year Ended December 31,** | **Year Ended December 31,** |  |  |  |  |  |  |
|  | **Year Ended December 31,** | **Year Ended December 31,** |  |  |  |  |  |  |
|  | **2022** | **2021** |  |  |  |  |  |  |
| New pet acquisition expense | $89500 | $78647 |  |  |  |  |  |  |
| Excluding: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | (9116) | (9160) |  |  |  |  |  |  |
| Acquisition cost | 80384 | 69487 |  |  |  |  |  |  |
| Net of: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Sign-up fee revenue | (4984) | (4954) |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Other business segment pet acquisition expense | (541) | (499) |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Pet acquisition expense for managing general agent policies | (443) |  |  |  |  |  |  |  |
| Net acquisition cost | $74416 | $64034 |  |  |  |  |  |  |
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
|  | **Dec. 31, 2022** | **Sept. 30, 2022** | **Jun. 30, 2022** | **Mar. 31, 2022** | **Dec. 31, 2021** | **Sept. 30, 2021** | **Jun. 30, 2021** | **Mar. 31, 2021** |
| New pet acquisition expense | $22457 | $22434 | $22982 | $21627 | $19845 | $19708 | $19390 | $19704 |
| Excluding: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | (2079) | (2108) | (2601) | (2328) | (2136) | (2112) | (2181) | (2731) |
| Acquisition cost | 20378 | 20326 | 20381 | 19299 | 17709 | 17596 | 17209 | 16973 |
| Net of: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Sign-up fee revenue | (1191) | (1339) | (1252) | (1202) | (1162) | (1268) | (1260) | (1264) |
| &nbsp;&nbsp;&nbsp;Other business segment pet acquisition expense | (65) | (181) | (186) | (109) | (76) | (134) | (118) | (171) |
| &nbsp;&nbsp;&nbsp;Pet acquisition expense for managing general agent policies | (443) |  |  |  |  |  |  |  |
| Net acquisition cost | $18679 | $18806 | $18943 | $17988 | $16471 | $16194 | $15831 | $15538 |

---

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): |
|  | **Year Ended December 31,** | **Year Ended December 31,** |  |  |  |  |  |  |
|  | **Year Ended December 31,** | **Year Ended December 31,** |  |  |  |  |  |  |
|  | **2022** | **2021** |  |  |  |  |  |  |
| Net loss | $(44672) | $(35530) |  |  |  |  |  |  |
| Excluding: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 32537 | 28226 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization expense | 10921 | 11965 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (3026) | (337) |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 4267 | 10 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-operating expenses | (1) | 2 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 476 | 310 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Business combination transaction costs | 372 | 82 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss from equity method investment | (131) | 6 |  |  |  |  |  |  |
| Adjusted EBITDA | $743 | $4734 |  |  |  |  |  |  |
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
|  | **Dec. 31, 2022** | **Sept. 30, 2022** | **Jun. 30, 2022** | **Mar. 31, 2022** | **Dec. 31, 2021** | **Sept. 30, 2021** | **Jun. 30, 2021** | **Mar. 31, 2021** |
| Net loss | $(9285) | $(12914) | $(13618) | $(8855) | $(7042) | $(6819) | $(9221) | $(12448) |
| Excluding: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 8412 | 8306 | 8462 | 7358 | 6808 | 6443 | 6527 | 8448 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization expense | 2897 | 2600 | 2707 | 2717 | 2770 | 2944 | 3158 | 3093 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (1614) | (1018) | (297) | (97) | (80) | (85) | (84) | (88) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 1587 | 1408 | 1193 | 79 | 9 |  | 3 | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-operating expenses |  |  | (1) |  |  | (1) | 3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense (benefit) | (15) | 496 | 19 | (24) | 1034 | (312) | (195) | (217) |
| &nbsp;&nbsp;&nbsp;&nbsp;Business combination transaction costs | 193 | 179 |  |  |  |  |  | 82 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss from equity method investment |  |  | (131) |  |  |  | 6 |  |
| Adjusted EBITDA | $2175 | $(943) | $(1666) | $1178 | $3499 | $2170 | $197 | $(1132) |

---

------

**<u>Contacts</u>:**

**Investors:**

Laura Bainbridge, Vice President, Corporate Communications

<u>Investor.Relations@trupanion.com</u>